Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 50, Issue 2, 2008, Pages 298-303

  Meister, Bernhard ^a   Kropshofer, Gabriele ^a   Klein Franke, Andreas ^a   Strasak, Alexander M ^a   Hager, Josef ^a   Streif, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Acute lymphoblastic leukemia; Antithrombin; Children; Enoxaparin; Low molecular weight heparin; Thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ESCHERICHIA COLI ASPARAGINASE; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAIN CIRCULATION; CANCER DIAGNOSIS; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; VENOUS CIRCULATION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITHROMBINS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; ENOXAPARIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VENOUS THROMBOEMBOLISM;

EID: 37549016792     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21222     Document Type: Article

References (18)

1. Kuhle S, Lau A, Bajzar L, et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol 2006; 134:526-531.
2. Korte W, Greiner J. PARKAA paves the way. Thromb and Haemost 2003;90:163-164.
3. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97: 508-516.
4. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595-1599.
5. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108:2216-2222.
6. Mazzucconi MG, Gugliotta L, Leone G, et al. Antithrombin-III infusion suppresses the hypercoagulable state in adult acute lymphoblastic-leukemia patients Treated with a low-dose of Escherichia coli L-asparaginase - a Gimema Study. Blood Coagul Fibrinol 1994;5:23-28.
7. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90: 235-244.
8. Monagle P, Michelson AD, Bovill E. Antithrombotic therapy in children. Chest 2001;119:344S-370S.
9. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003;101:2529-2533.
10. Athale UH, Siciliano SA, Crowther M, et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129:803-810.
11. Steinherz PG, Miller LP, Ghavimi F, et al. Dural sinus thrombosis in children with acute lymphoblastic leukemia. JAMA 1981;246: 2837-2839.
12. Priest JR, Ramsay NKC, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic-Leukemia. J Pediatr 1982;100: 984-989.
13. Hongo T, Okada S, Ohzeki T, et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 2002; 44:293-299.
14. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401-410.
15. Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005;128:291-302.
16. van der Heijden JF, Hutten BA, Buller HR, et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002; CD002001.
17. Kovacs MJ, Levine MN, Keeney M, et al. Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thromb Haemost 2005;93:1185-1188.
18. Sutor AH, Chan AK, Massicotte P. Low-molecular-weight heparin in pediatric patients. Semin Thromb Hemost 2004;30:31-39.